Someone else already paid for the growth: management describes an outside party bearing the cost, risk, or work that exp
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes an outside party already bearing the cost, risk, or work of expanding the company's business. Key points: Abbott deal for SurVeil DCB. Abbott has worldwide commercialization rights, Surmodics supplies product, collaborates on development, clinical trials, regulatory. Abbott received options for other programs. The revenue from Abbott is license fee revenue, recognized over time. The outside party (Abbott) is paying for commercialization rights, but is Abbott bearing the cost of expansion? The agreement: Surmodics supplies the product, collaborates on development, clinical trials, regulatory. Abbott has commercialization rights. But who bears the cost of clinical trials? The transcript says: "we will supply the SurVeil Drug-Coated Balloon to Abbott and collaborate with Abbott on product development, clinical trials and regulatory activities to obtain marketing approval." It doesn't explicitly say Abbott is funding the trials. However, the revenue recognition is tied to costs incurred. The $25 million upfront license fee is deferred and recognized over time. That suggests Abbott paid upfront for rights, but the ongoing costs of the trial are borne by Surmodics? Actually, the revenue recognition is based on costs incurred, so Surmodics is incurring costs and recognizing revenue proportionally. That implies Surmodics is bearing the cost of the trial, not Abbott. The outside party (Abbott) paid an upfront fee, but that's a payment for rights, not necessarily funding the expansion. The question asks: "someone other than the company is spending its own money, committing its own assets, or doing its own labor in a way that directly enlarges what this company sells, serves, or earns." Abbott is paying for commercialization rights, but the actual work of clinical trials and regulatory is done by Surmodics (with collaboration). Abbott is not doing the labor; they are paying for rights. The outside effort is real (Abbott has rights), but is Abbott bearing the cost of expansion? The expansion is the clinical trial and regulatory approval. Surmodics is doing that. Abbott is paying a license fee, but that's revenue to Surmodics, not Abbott bearing the cost.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| MGNX | MacroGenics, Inc. | Q3 2016 | 2016-11-02 | D |
| CRIS | Curis, Inc. | Q1 2016 | 2016-05-09 | C |
INST · Q4 2017 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing the Paychex partnership as a white-label reseller arrangement where Paychex is already bearing the cost, risk, and work of expanding Instructure’s business by offering Bridge Learn to its 0.5 million customers (6 million users) using its own salesforce and customer base — a real, underway effort since the partnership was entered into and integration is already in progress. Management explicitly states Paychex owns the customers and will sell the product, while Instructure is only powering the backend, and the resulting revenue is still mostly ahead (they are optimistic about significant success by year-end). This matches 100% of the required criteria.
PLAB · Q2 2017 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing the DNP JV as an outside party already bearing the bulk of the expansion costs and risks for the new China facility (the $160 million Xiamen site, previously announced as a company-led greenfield build last August). Peter Kirlin notes they will "utilize all cash held in Taiwan and greater reduced to risk of ramping of our new factory in China," while Sean Smith confirms they are "sharing that total investment of 160 million as we in essence have a 50-50 partnership, however we will consolidate it" and will "share equitably the startup cost.
YUM · Q2 2018 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing real, ongoing outside efforts by franchisees and partners already bearing the cost, risk, and work of expansion. Franchisees are actively spending their own capital to open units (e.g., 482 net new units YTD vs. 317 last year; KFC opening nearly 200 2Q units; Pizza Hut 6% net new unit growth; Taco Bell 9 international units), with the company 97% franchised and on track for 98%. These efforts are already in motion and contributing to current results, while management highlights acceleration and future ramp (e.g.